A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Investigative Site 201, Berlin

Investigative Site 121, White Marsh

Investigative Site 101, Baltimore

Investigative Site 206, Lübeck

Investigative Site 116, Tampa

Investigative Site 202, Marburg

Investigative Site 118, Birmingham

Investigative Site 103, Cincinnati

Investigative Site 110, Indianapolis

Investigative Site 204, Münster

Investigative Site 124, Normal

Investigative Site 123, Lafayette

Investigative Site 108, Little Rock

Investigative Site 210, München

Investigative Site 109, Boise

Investigative Site 111, Murray

Investigative Site 105, San Diego

Investigative Site 115, Seattle

Investigative Site 209, Dresden